Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Southern Copper Corp (SCCO) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade
Southern Copper CorpTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs Southern Copper Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B), while Southern Copper Corp trades at $209.14 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 13.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Southern Copper Corp pays a 2.21% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Southern Copper Corp for 61 Days on average.

HALOSCCO
Market Cap
$12.58B$167.74B
Volume
2,179,278853,110
Sector
HealthBasic Materials
52-Week High
$115.22$219.70
52-Week Low
$61.63$120.02
Typical Hold Time
1 Days61 Days
Enterprise Value
$14.49B$169.03B
Dividend Yield
—2.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Southern Copper Corp

Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.

SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HALO

No sentiment data available yet.

SCCO
14% Buy86% Sell
Avg holding period · 61 Days

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

Read more on HALO →

About Southern Copper Corp

Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.

Read more on SCCO →